Biocartis

LAUSANNE, Switzerland, November 30, 2011 - Current Ceo Rudi Pauwels Becomes Executive Chairman Focusing On Scientific And Technology Strategy New CeoAppointment Strengthens Commercial Focus As BiocartisPrepares ForLaunch Of ItsFirst Product In 2013 Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive personalized medicine and improve the diagnosis of disease, today announced the appointment of Dr.

LAUSANNE, Switzerland, November 17, 2011 - Funds Will be Used to Commercialize a Fully Automated, Compact Molecular Diagnostics System Designed to Drive the Widespread Adoption of Personalized Medicine and Other Diagnostic Applications Including the Fight Against Infectious Disease Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive the widespread adoption of personalized medicine and other applications including the improved diagnosis of infectious disease, announced today the completion of EUR 71 million (USD 100 million) Series C equity fund raising backed by existing investors, new investors and industrial collaborators and partners.

MARCY L'ETOILE, France and LAUSANNE, Switzerland, November 4, 2010 - - Co-development of Assays and Co-distribution of a Fully Integrated Molecular Platform due for Launch in 2012 - bioMerieux Gains Exclusive Rights in Microbiology - bioMerieux Takes Equity Stake in Biocartis bioMerieux and Biocartis announced today that they have entered into a strategic agreement to co-develop assays on Biocartis' fully integrated molecular diagnostics system, which the two companies will co-distribute starting in 2012.

LAUSANNE, Switzerland, April 8, 2010 - Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round.

LAUSANNE, Switzerland - Biocartis SA, a diagnostics company focused on fast and low-cost, integrated molecular and immunodiagnostics based on its proprietary micro-technology platform, today announced the successful closing of a Series A equity financing round.